Molecular Therapeutics

Type: Company
Name: Molecular Therapeutics
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency

†Center for Discovery and Innovation in Parasitic Diseases, ‡Department of Pathology and §Department of Medicine, Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94158, United States Cellular Ultra-Structure ... [Published Journal of Medicinal Chemistry - Aug 19 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Research Leader Looks Beyond Genetic Mechanisms of Acquired Resistance to TKI Therapies

Jeff Settleman, PhDJeff Settleman, PhD, oversees efforts to identify and validate targets for oncology drug discovery and to discover predictive biomarkers for new cancer therapies. Prior to joining Genentech, Settleman spent 18 years on the faculty at ... [Published OncLive - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 1 reports

Oncothyreon Announces Acquisition of Alpine Biosciences

Oncothyreon to Leverage Alpine's Protocell Technology to Enable TargetedDelivery of Molecular Therapeutics for Serious DiseasesCompany to Hold Conference Call at 4:30 p.m. EDT TodaySEATTLE, WA, Aug. 11, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY), ... [Published PR Newswire: Financial Services - Aug 11 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 2 reports

Ignyta Appoints Adrian Senderowicz, M.D., as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs

SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Adrian Senderowicz, M.D., has been appointed as Chief Medical Officer and Senior Vice President, Clinical Development ... [Published Investor's Business Daily - Aug 11 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Altering the circadian rhythm: an interview with Dr. Doug Kojetin, The Scripps Research Institute

Almost Family records net service revenues of $125 million for Q2 2014BioDelivery Sciences updates on Clonidine Topical Gel Phase 3 trial for PDN treatment Interview conducted by April Cashin-Garbutt, BA Hons (Cantab)Dr. Douglas Kojetin THOUGHT LEADERS ... [Published News-Medical.Net - Aug 07 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Scientists Find Genetic Mutations Linked to Salivary Gland Tumours

Michael Conkright, PhD, is a biologist in the Department of Molecular Therapeutics at The Scripps Research Institute, Florida campus. Image: Courtesy of The Scripps Research InstituteOncogenomics   August 05, 2014Jupiter, FL (Scicasts) — Research conducted ... [Published Scicasts - Aug 05 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

De novo activation of MYC by CRTC1/MAML2 [Biochemistry]

Antonio L. Amelio a , 1 , Mohammad Fallahi b , Franz X. Schaub a , Min Zhang c , Mariam B. Lawani a , Adam S. Alperstein a , Mark R. Southern d , Brandon M. Young e , Lizi Wu f , Maria Zajac-Kaye c , g , Frederic J. Kaye c , John L. Cleveland ... [Published PNAS - Jul 29 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center

OncLive® is pleased to announce that UNC Lineberger Comprehensive Cancer Center has joined its Strategic Alliance Partnership program.By participating in the Strategic Alliance Partnership program, UNC Lineberger will have the opportunity to work with ... [Published Bio-Medicine - Jul 23 2014]
First reported Apr 21 2014 - Updated Apr 22 2014 - 1 reports

HERS Breast Cancer Foundation Event Honors Community Leadership in...

The fifth annual People with Purpose Awards Luncheon on April 24 recognizes the contributions of local nonprofits, business leaders, and doctors in support of breast cancer survivors. HERS Breast Cancer Foundation today announced that they are hosting ... [Published PRWeb - Apr 21 2014]

Quotes

...chnology-transfer and economic-development organization of UNM, which began collaborating with Alpine Biosciences on the protocell platform in 2013. "We look forward to collaborating with Oncothyreon in the future as they advance this platform."
...Dr. Allison is a breast cancer survivor and author of "Red Sunshine: A Story of Strength and Inspiration from a Doctor Who Survived Stage 3 Breast Cancer."

More Content

All (13) | News (10) | Reports (0) | Blogs (2) | Audio/Video (1) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
4-Aminopyridyl-Based CYP51 Inhibitors as Anti-... [Published Journal of Medicinal Chemistry - Aug 19 2014]
Research Leader Looks Beyond Genetic Mechanisms... [Published OncLive - Aug 12 2014]
Oncothyreon Announces Acquisition of Alpine Bio... [Published TickerTech.com - Aug 11 2014]
Oncothyreon Announces Acquisition of Alpine Bio... [Published PR Newswire: Financial Services - Aug 11 2014]
Ignyta Appoints Adrian Senderowicz, M.D., as Ch... [Published Investor's Business Daily - Aug 11 2014]
Ignyta Appoints Adrian Senderowicz, M.D., as Ch... [Published Benzinga.com - Aug 11 2014]
Altering the circadian rhythm: an interview wit... [Published News-Medical.Net - Aug 07 2014]
Scientists Find Genetic Mutations Linked to Sal... [Published Scicasts - Aug 05 2014]
De novo activation of MYC by CRTC1/MAML2 [Bioch... [Published PNAS - Jul 29 2014]
OncLive Expands Its Strategic Alliance Partners... [Published Bio-Medicine - Jul 23 2014]
HERS Breast Cancer Foundation Event Honors Comm... [Published PRWeb - Apr 21 2014]
The Humor Code [Published Slate Magazine - Mar 27 2014]
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Oncothyreon Announces Acquisition of Alpine Bio... [Published PR Newswire: Financial Services - Aug 11 2014]
Oncothyreon to Leverage Alpine's Protocell Technology to Enable TargetedDelivery of Molecular Therapeutics for Serious DiseasesCompany to Hold Conference Call at 4:30 p.m. EDT TodaySEATTLE, WA, Aug. 11, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY), ...
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
Forbion Capital Partners -backed uniQure , which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ . Jefferies and Leerink Partners acted as joint book-running managers and Piper ...
1

Audio/Video

sort by: Date | Relevance
The Humor Code [Published Slate Magazine - Mar 27 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.